Anovulation is a common cause of infertility with poly cystic ovarian disease being the commonest.
Objective
To estimate the prevalence of various causes of anovulation in patients younger than 35 years of age attending infertility clinics and to ascertain the nature and extent of metabolic abnormalities and efficacy of therapy.
Materials and methods
Sixty cases of anovulatory infertility diagnosed by standard method were recruited for the study. Transvaginal sonography and hormonal profile like LH, FSH, Prolactin and Thyroid profile evaluated to establish the cause of anovulation. Menstrual history, Body Mass Index, Waist Hip ratio and presence of hirsutism, acanthosis nigricans were recorded. Metabolic parameters like lipid profile, OGTT and Glucose insulin ratio were also assessed. All parameters were reevaluated at 3 and 6 months of treatment and were statistically analyzed. Response to treatment in terms ovulation and pregnancy achieved was also analyzed.
Conclusion
Women with anovulatory infertility has shown good improvement to appropriate treatment.
How to cite this article
Bhandoria G, Rudra S. Anovulatory Infertility: A Prospective Study. Int J Infertility Fetal Med 2013; 4(1):18-23.
Clinical gynecological endocrinology and infertility (7th ed). Lippincott Williams and Wilkins 2010.
Metformin decreases hyperandrogenism and hyperinsulinemia in women with PCOS. Fertl Stril 2000;73: 6-12.
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293:355-59.
Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Human Reprod 2006;21(7):1925-34.
Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: A controlled, populationbased study. Am J Obstet Gynecol 2001;184:289-96.
Prevalence and predictions of the risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-74.
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: A randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007;22(11):2967-73.
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005;20(12):3333-40.
Luteinizing hormone receptors in ovarian follicles of patients with polycystic ovarian disease. J Clin Endocrinol Metab 1980;51:1054-57.
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17_activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-79.
Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999;14:2963-68.
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54.
Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: A randomized, controlled trial. Hum Reprod 2003;18(2):299-304.
Serum prolactin levels and the value of bromocriptine in the treatment of anovulatory infertility. BJOG 1977;84:58-66.
Thyroid disease and female reproduction. Fertil Steril 2000;74(6):1063-70.
Disorders of thyroid function and fertility disorders. Ceska Gynekol 2000;65(1):53-57.
Thyroid and ovarian function in infertile women. Hum Reprod 1991;6(3):338-45.
